IRulya Therapeutics IRLA Chief Operating Officer · filings 2026 to 2026
No transactions in the filings read; Form 144 notices are listed above.
Person · CIK 2159394
Keith R. Fandrick
Chief Operating Officer at IRulya Therapeutics
Sold on Form 4$0
Noticed on Form 144$0
Bought on Form 4$0
Companies1
Holdings now
As reported after the latest Form 3, 4 or 5 at each company.
How these figures work
Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.
| Company | Security | Held | Shares or units | As of |
|---|---|---|---|---|
| IRulya Therapeutics IRLA | Employee Stock Option (Right to Buy) exercise $16.81, expires May 11, 2036, into Common Stock | Directly | 92,168 | Oct 8, 2026 · Filing · EDGAR |
| IRulya Therapeutics IRLA | Employee Stock Option (Right to Buy) exercise $16.81, expires May 11, 2036, into Common Stock | Directly | 92,168 | Oct 8, 2026 · Filing · EDGAR |
| IRulya Therapeutics IRLA | Employee Stock Option (Right to Buy) exercise $1.81, expires Mar 15, 2036, into Common Stock | Directly | 30,442 | Oct 8, 2026 · Filing · EDGAR |
| IRulya Therapeutics IRLA | Employee Stock Option (Right to Buy) exercise $1.81, expires Mar 15, 2036, into Common Stock | Directly | 5,626 | Oct 8, 2026 · Filing · EDGAR |
| IRulya Therapeutics IRLA | Employee Stock Option (Right to Buy) exercise $1.81, expires Mar 14, 2034, into Common Stock | Directly | 5,278 | Oct 8, 2026 · Filing · EDGAR |
| IRulya Therapeutics IRLA | Employee Stock Option (Right to Buy) exercise $1.81, expires Aug 12, 2034, into Common Stock | Directly | 3,026 | Oct 8, 2026 · Filing · EDGAR |
| IRulya Therapeutics IRLA | Employee Stock Option (Right to Buy) exercise $1.80, expires Feb 10, 2035, into Common Stock | Directly | 2,774 | Oct 8, 2026 · Filing · EDGAR |
| IRulya Therapeutics IRLA | Employee Stock Option (Right to Buy) exercise $1.81, expires Jan 26, 2033, into Common Stock | Directly | 1,213 | Oct 8, 2026 · Filing · EDGAR |
| IRulya Therapeutics IRLA | Employee Stock Option (Right to Buy) exercise $1.81, expires Jan 26, 2032, into Common Stock | Directly | 346 | Oct 8, 2026 · Filing · EDGAR |
| IRulya Therapeutics IRLA | Employee Stock Option (Right to Buy) exercise $1.81, expires Jul 24, 2027, into Common Stock | Directly | 173 | Oct 8, 2026 · Filing · EDGAR |
| IRulya Therapeutics IRLA | Employee Stock Option (Right to Buy) exercise $1.81, expires Mar 1, 2031, into Common Stock | Directly | 138 | Oct 8, 2026 · Filing · EDGAR |
| IRulya Therapeutics IRLA | Employee Stock Option (Right to Buy) exercise $1.80, expires Oct 19, 2030, into Common Stock | Directly | 104 | Oct 8, 2026 · Filing · EDGAR |
| IRulya Therapeutics IRLA | Employee Stock Option (Right to Buy) exercise $1.81, expires Oct 19, 2030, into Common Stock | Directly | 69 | Oct 8, 2026 · Filing · EDGAR |
| IRulya Therapeutics IRLA | Employee Stock Option (Right to Buy) exercise $1.84, expires Mar 1, 2031, into Common Stock | Directly | 34 | Oct 8, 2026 · Filing · EDGAR |
Sold and noticed by quarter
No sales or Form 144 notices with a stated value.
Every transaction, by company
Each Form 3, 4 and 5 transaction in plain words, newest first.
How these figures work
Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.
All 1 Forms 3, 4, 5 and 144
| Filed | Form | Company | Links |
|---|---|---|---|
| Oct 19, 2026 | Form 3 | IRulya Therapeutics IRLA | Filing · EDGAR |
Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.